Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525839 | 0.89 | MCHR1 (0.72) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL12838140 | 0.88 | MCHR1 (0.71) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14537241 | 0.86 | MCHR1 (0.69) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL12838278 | 0.84 | MCHR1 (0.85) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL12838073 | 0.83 | MCHR1 (0.84) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL12838179 | 0.83 | MCHR1 (0.81) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL1531323 | 0.83 | MCHR1 (1.00) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14537246 | 0.82 | MCHR1 (0.82) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14537145 | 0.82 | MCHR1 (0.82) | MCHR1CHRM4CYP3A4CHRM5ADRA2A | |
| SCHEMBL14537144 | 0.82 | MCHR1 (0.81) | MCHR1CHRM4CYP3A4CHRM5ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-1948665-B1 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | MCHR1 1/4885CHRM4 569/4885CYP3A4 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.